

People featured are compensated by Gilead.

You Are Unlike Any Other

And HIV doesn't change that.

Ask your healthcare provider if BIKTARVY® is right for you.

BIKTARVY is a complete, 1-pill, once-a-day prescription medicine used to treat HIV-1 in certain adults. **BIKTARVY does not cure HIV-1 or AIDS.**



BIKTARVY®

bictegravir 50mg/emtricitabine 200mg/
tenofovir alafenamide 25mg tablets

Click to see Important Facts about [BIKTARVY®](#), including important warnings on worsening of hepatitis B infection, on page 20.



Table of Contents

Living With HIV	3
About BIKTARVY®	4
BIKTARVY Studies	5
Starting Treatment	6
Switching Treatments	9
Understanding Resistance	11
Possible Side Effects	15
Partnering With Your Healthcare Provider	16
Prioritizing Yourself	17
Support and Resources	18

Keep Being *You*

You are unlike any other. And HIV doesn't change that.

When taken as prescribed, HIV treatment can help you get to and stay undetectable, so **you can keep being yourself**.

Today's medicines have helped people live healthy with HIV. While there is no cure for HIV, finding a treatment that's right for you can help suppress the virus. Don't wait to talk to your healthcare provider. Talk about your treatment options as soon as you are diagnosed.

Taking HIV medicine as prescribed helps the body fight HIV.

- ◆ HIV medicines can lower the amount of virus in the blood **to levels that are undetectable**. That means the amount of virus is so low it can't be measured in a lab test.
- ◆ Lowering the amount of virus in the blood helps increase CD4 T-cells (the number of cells that fight infections in the body), strengthening the immune system.

U=U

Undetectable = Untransmittable

According to the US Department of Health and Human Services (DHHS), taking HIV treatment as prescribed and getting to and staying undetectable prevents transmitting HIV through sex.

For more
information about
living with HIV,
click [here](#).



Remember, take your HIV medicine as your healthcare provider prescribes. This helps you live healthy with HIV and keep your virus undetectable.



BIKTARVY®

bictegravir 50mg/emtricitabine 200mg/
tenofovir alafenamide 25mg tablets

Click to see Important Facts about [BIKTARVY®](#), including important warnings about BIKTARVY, on page 20.

"I am much more than my diagnosis. It is part of my life, but it's not everything."

D'Eva

Switched to BIKTARVY®
6 years ago,
still undetectable

IMPORTANT SAFETY INFORMATION

What is the most important information I should know about BIKTARVY®?

BIKTARVY may cause serious side effects:

- ◆ **Worsening of hepatitis B (HBV) infection.** Your healthcare provider will test you for HBV. If you have both HIV-1 and HBV and stop taking BIKTARVY, your HBV may suddenly get worse. Do not stop taking BIKTARVY without first talking to your healthcare provider, as they will need to monitor your health, and may give you HBV medicine.



BIKTARVY®

bictegravir 50mg/emtricitabine 200mg/
tenofovir alafenamide 25mg tablets

Learn More About the *#1 Prescribed* HIV Treatment

Source: IQVIA LAAD, July 2018 through July 2024.*

Over 430,000 people in the United States take BIKTARVY® for their HIV treatment.

Source: IQVIA LAAD, March 2021 through July 2024.†

BIKTARVY IS:



Not actual size
(15 mm x 8 mm)

- ◆ A complete HIV-1 treatment
- ◆ 1 small pill
- ◆ Taken with or without food
- ◆ Can be taken anywhere
- ◆ Taken once a day, at any time of day

Take BIKTARVY exactly as your healthcare provider tells you to take it, and do not miss a dose. Do not change your dose or stop taking BIKTARVY without first talking with your healthcare provider.

BIKTARVY is a prescription medicine for adults and children with HIV-1 who weigh at least 31 lbs and who are either:

- ◆ new to HIV-1 treatment **OR** ◆ replacing their current regimen
- ◆ For adults and children replacing their current regimen, their healthcare provider must determine if they meet certain requirements, including having an undetectable viral load (less than 50 copies/mL)

BIKTARVY does not cure HIV-1 or AIDS. HIV is the virus that causes AIDS.

Children weighing at least 31 pounds to less than 55 pounds take a lower-dose tablet of BIKTARVY containing 30 mg bictegravir, 120 mg emtricitabine, and 15 mg tenofovir alafenamide once daily with or without food.

Ask your healthcare provider if BIKTARVY is right for you.

*This information is an estimate derived from the use of information under license from the following IQVIA information service: IQVIA LAAD, for the period July 2018 through July 2024. IQVIA expressly reserves all rights, including rights of copying, distribution, and republication.

†This information is an estimate derived from the use of information under license from the following IQVIA information service: IQVIA LAAD, for the period March 2021 through July 2024. IQVIA expressly reserves all rights, including rights of copying, distribution, and republication.

Click to see Important Facts about [BIKTARVY®](#), including important warnings about BIKTARVY, on page 20.



A *Treatment* Studied With You in Mind

BIKTARVY® has been thoroughly tested in 9 clinical trials with over 3600 participants.

HIV can affect anyone. BIKTARVY was studied in people from many different backgrounds, such as:



People **new** to starting treatment



People who **switched** after being undetectable on another treatment



Various **rac**es and **eth**nicities



People aged **3 to 80 years old**



Pregnant people



People with **high amounts of HIV** in the blood



People with a **low CD4 count**



People whose **HIV is resistant** to certain kinds of medicines

Studied With Resistance in Mind

Sometimes HIV can change or mutate. This change might make your medicines not work as well. **This is called a *resistance mutation* or *treatment resistance*.** It's important to understand resistance and what it means for your HIV treatment.

Learn more about how BIKTARVY studies were designed on [page 7](#) and why resistance matters on [page 11](#).



BIKTARVY®

bictegravir 50mg/emtricitabine 200mg/
tenofovir alafenamide 25mg tablets

Click to see Important Facts about [BIKTARVY®](#), including important warnings about BIKTARVY, on [page 20](#).

Starting HIV Treatment

When you're diagnosed with HIV, it's important to start treatment right away.

According to the US Department of Health and Human Services (DHHS), many patients can get to undetectable in as quickly as 8 to 24 weeks when taking their treatment as prescribed.

Some people are even able to start treatment the same day as diagnosis.

An HIV treatment, when taken as prescribed, may reduce the amount of HIV in the body to an undetectable level. Being undetectable can help you live healthy with HIV.



WHAT TO EXPECT WHEN STARTING TREATMENT

Some patients may be able to start BIKTARVY® right away. Before starting treatment, your healthcare provider will perform some tests to make sure it's the right fit for your needs. These tests will include:

- Testing for hepatitis B
- Determining if your HIV is resistant to any medications
- Checking your CD4 count
- Measuring the amount of HIV virus in your blood

Talk to your healthcare provider about whether you may be able to start BIKTARVY right away, even the same day as your diagnosis. Starting HIV-1 treatment is an important decision. Your healthcare provider will help determine if BIKTARVY is right for you.



Important Reminders:

- Do not change your dose or stop taking BIKTARVY without first talking with your healthcare provider
- Stay under a healthcare provider's care when taking BIKTARVY

Tamera

Started on BIKTARVY® in 2018,
still undetectable

STARTING TREATMENT

People featured are compensated by Gilead.

UNDERSTANDING TYPES OF TREATMENTS

How different types of HIV medicines work together to fight the virus.

Drug classes

HIV medicines are grouped into different drug classes according to how they fight HIV. Complete HIV treatment regimens combine more than one drug class to fight HIV.

Integrase strand inhibitor (INSTI)

INSTI is a class of drugs used to fight HIV at a certain part of the HIV life cycle. **BIKTARVY is the only treatment containing the INSTI bictegravir.**

Single-tablet regimen (STR)

A single-tablet regimen is a treatment for HIV where all the medicines you need are combined into one pill.

BIKTARVY® is the only INSTI-based STR recommended by DHHS guidelines for a same-day start for those who meet certain requirements.



BIKTARVY®

bictegravir 50mg/emtricitabine 200mg/
tenofovir alafenamide 25mg tablets

Click to see Important Facts about [BIKTARVY](#)®, including important warnings about BIKTARVY, on page 20.

Proven by Experience in Clinical Trials


BIKTARVY® has been proven effective in extensive clinical trials of people new to treatment.

CLINICAL TRIAL OVERVIEW

Study 1489 and Study 1490 | 5 years



Two studies involved more than 1200 adults new to HIV-1 treatment



At the end of 3 years, most adults who had been taking BIKTARVY continued, and many who were taking other treatments switched to BIKTARVY.

Together, these studies examined BIKTARVY in adults new to HIV treatment for a total of 5 years, and included over 120 women.

RESULTS

Both 3-year and 5-year clinical study time points showed that most adults new to treatment taking BIKTARVY as prescribed **reached and stayed undetectable** (less than 50 copies/mL).

[†]In one trial, the other treatment was TRIUMEQ® (abacavir, dolutegravir, lamivudine). In the other trial, the other treatment was DESCOVY® (emtricitabine, tenofovir alafenamide) + TIVICAY® (dolutegravir).

“I’m resilient, hopeful, and powerful, and I’m proud to be defined by who I am and what I stand for.”

Chad

Started on BIKTARVY® in 2018, still undetectable

STARTING TREATMENT

Who should not take BIKTARVY®?

Do not take BIKTARVY if you take:

- ♦ dofetilide
- ♦ rifampin
- ♦ any other medicines to treat HIV-1

What are the other possible side effects of BIKTARVY?

Serious side effects of BIKTARVY may also include:

- ♦ **Changes in your immune system.** Your immune system may get stronger and begin to fight infections that may have been hidden in your body. Tell your healthcare provider if you have any new symptoms after you start taking BIKTARVY.



BIKTARVY®

bictegravir 50mg/emtricitabine 200mg/
tenofovir alafenamide 25mg tablets

Click to see Important Facts about [BIKTARVY®](#), including important warnings about BIKTARVY, on page 20.

Proven *Results*

Proven effective for people new to HIV treatment in 2 clinical trials.



IN BOTH TRIALS:

1
year

About 9 out of 10 people

living with HIV who were new to treatment on BIKTARVY® **reached undetectable levels.**

Study 1489

92% (290 out of 314) of people on BIKTARVY reached undetectable compared to 93% (293 out of 315) of people on TRIUMEQ®.

Study 1490

89% (286 out of 320) of people on BIKTARVY reached undetectable compared to 93% (302 out of 325) of people on DESCOVY® + TIVICAY®.

3
years

8 out of 10 people

living with HIV who were new to treatment on BIKTARVY **reached undetectable levels.**

Study 1489

82% (256 out of 314) of people on BIKTARVY reached undetectable compared to 84% (265 out of 315) of people on TRIUMEQ.

Study 1490

81% (262 out of 320) of people on BIKTARVY reached undetectable compared to 84% (273 out of 325) of people on DESCOVY + TIVICAY.

5
years

At 5 years, most adults new to treatment taking BIKTARVY as prescribed **reached and stayed undetectable.**

Always work with your healthcare provider to decide which medicine makes sense for you. Learn about safety information from these studies and Important Safety Information about BIKTARVY on [page 15](#).



BIKTARVY®

bictegravir 50mg/emtricitabine 200mg/
tenofovir alafenamide 25mg tablets

STARTING TREATMENT



“I’m in a place where I can proudly be who I am. Staying on treatment and getting to undetectable is important to me.”

Elias
On BIKTARVY®
for 6 years

Serious side effects of BIKTARVY® may also include: (cont'd)

- ◆ **Kidney problems, including kidney failure.** Your healthcare provider should do blood and urine tests to check your kidneys. If you develop new or worse kidney problems, they may tell you to stop taking BIKTARVY.
- ◆ **Too much lactic acid in your blood (lactic acidosis),** which is a serious but rare medical emergency that can lead to death. Tell your healthcare provider right away if you get these symptoms: weakness or being more tired than usual, unusual muscle pain, being short of breath or fast breathing, stomach pain with nausea and vomiting, cold or blue hands and feet, feel dizzy or lightheaded, or a fast or abnormal heartbeat.

Click to see Important Facts about [BIKTARVY®](#), including important warnings about BIKTARVY, on page 20.

More People Have *Switched*


to BIKTARVY® than any other HIV treatment.

Source: IQVIA LAAD, July 2018 through July 2024.[§]

Talk to your doctor about whether switching to BIKTARVY can help you stay undetectable.

CLINICAL TRIAL OVERVIEW

Study 1844 | 3 years



RESULTS

At 1 year, about 9 out of 10 people (94%, 264 out of 282) who were undetectable on another treatment stayed undetectable when they switched to BIKTARVY in clinical trials. Of the people who continued their current treatment, about 9 out of 10 (95%, 267 out of 281) stayed undetectable at 1 year.

Both 1-year and 3-year time points showed that most adults who replaced their current treatment with BIKTARVY and took their treatment as prescribed **stayed undetectable**.

Serious side effects of BIKTARVY® may also include: (cont'd)


- ♦ **Severe liver problems**, which in rare cases can lead to death. Tell your healthcare provider right away if you get these symptoms: skin or the white part of your eyes turns yellow, dark “tea-colored” urine, light-colored stools, loss of appetite for several days or longer, nausea, or stomach-area pain.

The most common side effects of BIKTARVY in clinical studies were diarrhea (6%), nausea (6%), and headache (5%). Tell your healthcare provider if you have any side effects that bother you or don’t go away.

Switching your HIV treatment is an important decision. Always work with your healthcare provider to decide which medicine makes sense for you.

CLINICAL TRIAL OVERVIEW

Study 1878 | 2 years



RESULTS

At 1 year, about 9 out of 10 people (92%, 267 out of 290) who were undetectable on another treatment stayed undetectable when they switched to BIKTARVY in clinical trials. Of the people who continued their current treatment, about 9 out of 10 (89%, 255 out of 287) stayed undetectable at 1 year.

Both 1-year and 2-year time points showed that most adults who replaced their current treatment with BIKTARVY and took their treatment as prescribed **stayed undetectable**.

Always work with your healthcare provider to decide which medicine makes sense for you. Learn about safety information from these studies and Important Safety Information about BIKTARVY on [page 15](#).

[§]This information is an estimate derived from the use of information under license from the following IQVIA information service: IQVIA LAAD, for the period July 2018 through July 2024. IQVIA expressly reserves all rights, including rights of copying, distribution, and republication.

^{||}The continued treatment was TRIUMEQ (abacavir, dolutegravir, lamivudine).

[†]The continued treatments were a combination of either EPZICOM® (abacavir, lamivudine) or TRUVADA® (emtricitabine, tenofovir disoproxil fumarate) + atazanavir or darunavir (with cobicistat or ritonavir).

Built for the *Journey*

The 3 powerful medicines in BIKTARVY® were designed to attack the virus and work together to lower the amount of HIV in your blood to undetectable levels.

POWERS WHAT MATTERS MOST



When taken as prescribed, BIKTARVY can help lower the amount of HIV in your blood to undetectable levels.




You may be able to start BIKTARVY as soon as you're diagnosed and begin your treatment journey. Or, if you are switching treatments, BIKTARVY may be an option for you.

Talk to your healthcare provider to see if **BIKTARVY is the right option for you.**



BIKTARVY®

bictegravir 50mg/emtricitabine 200mg/
tenofovir alafenamide 25mg tablets



Dimitri

Started on BIKTARVY® in 2018,
still undetectable

What should I tell my healthcare provider before taking BIKTARVY?

- ◆ **All your health problems.** Be sure to tell your healthcare provider if you have or have had any kidney or liver problems, including hepatitis virus infection.
- ◆ **All the medicines you take,** including prescription and over-the-counter medicines, antacids, laxatives, vitamins, and herbal supplements. BIKTARVY and other medicines may affect each other. Keep a list of all your medicines and show it to your healthcare provider and pharmacist, and ask if it is safe to take BIKTARVY with all of your other medicines.

Click to see Important Facts about [BIKTARVY®](#), including important warnings about BIKTARVY, on page 20.

Defending Against Resistance Matters

Taking medicine with a high barrier to resistance and sticking to your treatment can help defend against developing drug resistance.

WHAT IS RESISTANCE?

Sometimes, HIV can change or mutate. This change might make a medicine not work as well. This is called a *resistance mutation* or *treatment resistance*. When HIV becomes resistant, it's tougher to treat. Resistance is permanent and not reversible, which means future treatment options could be limited. That's why it's important to understand ways to reduce the risk of resistance.

HOW DOES HIV BECOME RESISTANT?

- ◆ **From the start:** When someone acquires HIV, it is possible that the HIV virus is already resistant to certain medicines. This is called “preexisting resistance,” and it means some treatments won’t work even before they are used.
- ◆ **Over time:** If HIV changes after treatment starts, it can become resistant and affect how well the treatment works. Your viral load can increase if you don’t take your HIV medicines as prescribed, if you miss doses, or if you stop treatment. This is one way you can develop drug resistance.

Make sure to take your treatment as prescribed because low levels of medicine in your blood may make it easier for the HIV virus to mutate or change.

The Importance of a High Barrier to Resistance

Medicines have low to high barriers to resistance, which tell us how many mutations would need to occur to stop the medicine from working. **A medicine with a high barrier to resistance means it can still work even after several mutations.** An important defense against drug resistance is choosing a treatment with a **high barrier to resistance** and taking it exactly as your healthcare provider prescribes.

Make sure to discuss resistance with your healthcare provider. They can help you understand why barriers to resistance matter.



BIKTARVY®
bictegravir 50mg/emtricitabine 200mg/
tenofovir alafenamide 25mg tablets



People featured are compensated by Gilead.

Click to see Important Facts about [BIKTARVY®](#), including important warnings about BIKTARVY, on page 20.

Zero Cases of Resistance Over 5 Years



Resistance

Zero adults new to treatment developed drug resistance to BIKTARVY® through 5 years of clinical trials.



BIKTARVY, which contains a unique combination of medicines including bicitgravir, provides a high barrier to resistance.

Taking a treatment with a high barrier to resistance, like BIKTARVY, and taking your medication as prescribed can help prevent drug resistance.

What should I tell my healthcare provider before taking BIKTARVY®? (cont'd)

- ◆ **If you are pregnant** or plan to become pregnant. Tell your healthcare provider if you become pregnant while taking BIKTARVY.
- ◆ **If you are breastfeeding** (nursing) or plan to breastfeed. Talk to your healthcare provider about the risks of breastfeeding during treatment with BIKTARVY.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.



BIKTARVY®

bicitgravir 50mg/emtricitabine 200mg/
tenofovir alafenamide 25mg tablets



Start the conversation
with your healthcare
provider about why
resistance matters.

Hugo

On BIKTARVY®
for 6 years

Can Keep *Working* Even if HIV Has Changed

BIKTARVY® was proven to keep working in clinical trials even when HIV has changed in certain ways.

One BIKTARVY study involved more than 560 adults, some of who had an HIV virus with a resistance mutation called M184V/I.

- ◆ People in the study either switched or continued their current treatment. 284 switched treatment with BIKTARVY, and 281 stayed on or switched their treatment with DESCOVY® (emtricitabine, tenofovir alafenamide) + TIVICAY® (dolutegravir) over a 1-year period.
- ◆ Of the adults who switched to BIKTARVY, 47 out of 284 had an HIV virus that had changed in a certain way (a mutation called M184V/I) so that it was resistant to emtricitabine, a medicine in BIKTARVY.

BIKTARVY can help adults stay undetectable whose virus has changed in a certain way (a mutation called M184V/I), where it is resistant to emtricitabine, a medicine in BIKTARVY. Before taking BIKTARVY, your healthcare provider must determine that you meet certain requirements.


Zero cases of resistance

to BIKTARVY through 48 weeks, including those with HIV that had a resistance mutation.



BIKTARVY®

bictegravir 50mg/emtricitabine 200mg/
tenofovir alafenamide 25mg tablets



Denise

Switched to
BIKTARVY® in 2019,
still undetectable

IMPORTANT SAFETY INFORMATION

What is the most important information I should know about BIKTARVY®?

BIKTARVY may cause serious side effects:

- ◆ **Worsening of hepatitis B (HBV) infection.** Your healthcare provider will test you for HBV. If you have both HIV-1 and HBV and stop taking BIKTARVY, your HBV may suddenly get worse. Do not stop taking BIKTARVY without first talking to your healthcare provider, as they will need to monitor your health, and may give you HBV medicine.

Click to see Important Facts about [BIKTARVY®](#), including important warnings about BIKTARVY, on page 20.

An Established *Safety* Profile

<1% OF ADULTS NEW TO TREATMENT STOPPED TAKING BIKTARVY® DUE TO RELATED SIDE EFFECTS#


- ◆ Less than 1% of adults new to treatment who initially started on BIKTARVY at the beginning of the clinical trials stopped taking BIKTARVY because of related side effects through 5 years.
- ◆ In clinical trials of adults living with HIV who were new to treatment and initially started on BIKTARVY in the beginning of the clinical trials, **no one stopped taking BIKTARVY due to bone-, kidney-, or liver-related side effects** through 5 years.

Of the patients who initially started on BIKTARVY at the beginning of the clinical trials, the most common side effects of BIKTARVY through 5 years, experienced in at least 5% of people in either study, were diarrhea, headache, and nausea.

Overall, the safety profile in clinical trials for people who switched to BIKTARVY, including those with the M184V/I mutation, was similar to that of people who were new to BIKTARVY.

These are not the only side effects of BIKTARVY. Tell your healthcare provider if you experience any side effects that bother you or do not go away.

#The side effects, also known as adverse events related to BIKTARVY that led patients to stop taking BIKTARVY over the 5-year studies were: weight gain; chest pain; bloating; sleep disorder; indigestion, tension headache, depressed mood, and insomnia; depression.



Who should not take BIKTARVY®?

Do not take BIKTARVY if you take:

- ◆ dofetilide
- ◆ rifampin
- ◆ any other medicines to treat HIV-1



Melanie

Switched to
BIKTARVY® in 2018,
still undetectable

People featured are compensated by Gilead.



BIKTARVY®

bictegravir 50mg/emtricitabine 200mg/
tenofovir alafenamide 25mg tablets

Understanding Possible Side Effects

The most common side effects of BIKTARVY® in clinical studies through 3 years were each experienced in at least 5% of people. In clinical studies of 634 adults new to HIV-1 treatment, the most common side effects were nausea (6%), diarrhea (6%), and headache (5%). These common side effects were each experienced by at least 1 out of 20 people ($\geq 5\%$).

These are not the only side effects of BIKTARVY. Tell your healthcare provider if you have any side effects that bother you or do not go away.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.

BIKTARVY may also cause serious side effects, including:

- ◆ **Changes in your immune system.** Your immune system may get stronger and begin to fight infections that may have been hidden in your body. Tell your healthcare provider if you have any new symptoms after you start taking BIKTARVY.
- ◆ **Kidney problems, including kidney failure.** Your healthcare provider should do blood and urine tests to check your kidneys. If you develop new or worse kidney problems, they may tell you to stop taking BIKTARVY.
- ◆ **Too much lactic acid in your blood (lactic acidosis),** which is a serious but rare medical emergency that can lead to death. Tell your healthcare provider right away if you get these symptoms: weakness or being more tired than usual, unusual muscle pain, being short of breath or fast breathing, stomach pain with nausea and vomiting, cold or blue hands and feet, feel dizzy or lightheaded, or a fast or abnormal heartbeat.
- ◆ **Severe liver problems,** which in rare cases can lead to death. Tell your healthcare provider right away if you get these symptoms: skin or the white part of your eyes turns yellow, dark “tea-colored” urine, light-colored stools, loss of appetite for several days or longer, nausea, or stomach-area pain.

Ask your healthcare provider if BIKTARVY is right for you and learn more at BIKTARVY.com.

Click to see Important Facts about [BIKTARVY®](#), including important warnings about BIKTARVY, on page 20.

Partnering With Your Healthcare Provider

Work closely with your healthcare provider to help ensure you have a treatment plan that best fits your needs.

HOW TO PARTNER WITH YOUR PROVIDER



Keep an open dialogue about your health, and be sure to let them know if anything has changed



Ask them about any other medicines or supplements you take—you can even ask your healthcare provider or pharmacist for a list of medicines that interact with BIKTARVY®



Be sure to attend your regularly scheduled appointments



Write down any questions you may have for your provider ahead of time, so you remember to ask during your appointment

For a list of questions and topics you may want to discuss with your healthcare provider, click the link below.
[BIKTARVY.com/Resources](https://www.biktaryv.com/Resources)

BIKTARVY® can affect the way other medicines work, and other medicines can affect how BIKTARVY works, which may cause serious side effects. Some medicines may also make the amount of BIKTARVY in your body too low to help keep your HIV-1 undetectable, and the virus may become resistant to BIKTARVY.

What should I tell my healthcare provider before taking BIKTARVY®?

- ◆ **Tell your healthcare provider your health history** and if you have or have had any kidney or liver problems, including hepatitis virus infection.
- ◆ **Tell your healthcare provider about all the medicines you take**, including prescription and over-the-counter medicines, antacids, laxatives, vitamins, and herbal supplements. Keep a list of your medicines and show it to your healthcare provider and pharmacist when you get a new medicine.
- ◆ **Do not start a new medicine without telling your healthcare provider.** Your healthcare provider can tell you if it is safe to take BIKTARVY with other medicines. You can ask your healthcare provider or pharmacist for a list of medicines that interact with BIKTARVY.

What if I am pregnant or breastfeeding or planning to become pregnant or breastfeed?

- ◆ **Tell your healthcare provider if you are pregnant** or plan to become pregnant while taking BIKTARVY.
- ◆ **If you are breastfeeding (nursing)** or plan to breastfeed, talk to your healthcare provider about the risks of breastfeeding during treatment with BIKTARVY.
- ◆ **If you are pregnant and take supplements or antacids that contain aluminum, magnesium, iron, or calcium**, talk to your healthcare provider about how to take BIKTARVY along with these supplements or antacids.

What should I do if I take too much?

If you take too much BIKTARVY, call your healthcare provider or go to the nearest hospital emergency room right away.

What should I do if I run out of medicine?

When your BIKTARVY supply starts to run low, get more from your healthcare provider or pharmacy. This is very important because the amount of virus in your blood may increase if the medicine is stopped even for a short time. The virus may develop resistance to BIKTARVY and become harder to treat.



BIKTARVY®

bictegravir 50mg/emtricitabine 200mg/
tenofovir alafenamide 25mg tablets

Click to see Important Facts about [BIKTARVY®](#), including important warnings about BIKTARVY, on page 20.

There's Only One You, so Prioritize *Yourself*

With treatment, one of the main goals is getting to and staying undetectable. But it's also important to think about your overall health and wellness.

Here are some ways to help you stay on track with your treatment and overall health:

- ◆ **Set Reminders and Automate:** Use your phone to set daily reminders and arrange for automatic prescription refills to ensure you never miss a dose
- ◆ **Stay Connected:** Have regular conversations with your healthcare provider and partner(s) to address any questions or concerns about your treatment
- ◆ **Create a Network of Care:** Lean on friends and family for encouragement
- ◆ **Focus on Overall Health:** Make choices for your physical health, such as eating a balanced diet, exercising, avoiding nicotine, and more
- ◆ **Support Your Mental Health:** Focus on your mental and emotional health.
To find support and resources, visit [BIKTARMV.com/Resources](https://www.biktarmv.com/resources)



Each step you take is a step toward living healthy with HIV. Talk to your healthcare provider about how to add these practices into your everyday life.



BIKTARMV®
bictegravir 50mg/emtricitabine 200mg/
tenofovir alafenamide 25mg tablets

“Get on treatment.
Stay on treatment.
And take care of
yourself.”

Nikki

Switched to
BIKTARMV® in 2018,
still undetectable

Click to see Important Facts about [BIKTARMV®](#), including
important warnings about BIKTARMV, on page 20.

Don't Let Cost Stand in Your Way

Insurance or no insurance, Gilead's Advancing Access® program may be able to help.



If you're eligible, Advancing Access® may be able to help you lower your co-pay to as little as \$0.** If you do not have insurance, you may be able to receive BIKTARVY® free of charge if you qualify for the Advancing Access Patient Assistance Program.

90% of people using the Gilead Advancing Access Co-pay Coupon Card program pay \$0 a month for BIKTARVY.

Source: Gilead Advancing Access co-pay program January 2023 – October 2024.

Advancing Access specialists can help you understand your health insurance and Gilead medication costs.

For more information, visit [GileadAdvancingAccess.com](https://www.gileadadvancingaccess.com) or call 1-800-226-2056, Monday-Friday, 9 AM to 8 PM ET.

Llame a la línea directa y pida hablar con un representante de habla hispana.

**Co-pay coupon support is available for commercially insured eligible patients only. Additional restrictions may apply. Subject to change; for full terms and conditions, visit www.gileadadvancingaccess.com/copay-coupon-card. This is not health insurance. Only accepted at participating pharmacies.



BIKTARVY®

bictegravir 50mg/emtricitabine 200mg/
tenofovir alafenamide 25mg tablets



Maricela

Switched to BIKTARVY®
in 2018, still undetectable

For more information and resources,
click [BIKTARVY.com/Resources](https://www.biktarvy.com/Resources).

Click to see Important Facts about [BIKTARVY](https://www.biktarvy.com)®, including
important warnings about BIKTARVY, on page 20.



BIKTARVY®

bictegravir 50mg/emtricitabine 200mg/
tenofovir alafenamide 25mg tablets



People featured are compensated by Gilead.

Meet extraordinary people

who take BIKTARVY®. Hear their stories and learn about BIKTARVY
by visiting [BIKTARVY.com/real-stories](https://www.gilead.com/real-stories).

Click to see Important Facts about [BIKTARVY®](#), including important warnings, on page 20.



BIKTARVY, the BIKTARVY Logo, ADVANCING ACCESS, GILEAD, the GILEAD Logo, GSI, and KEEP BEING YOU are trademarks of Gilead Sciences, Inc., or its related companies. All other marks referenced herein are the property of their respective owners.
© 2025 Gilead Sciences, Inc. All rights reserved. US-BVYC-0729 02/25



(bik-TAR-vee)

MOST IMPORTANT INFORMATION ABOUT BIKTARVY

BIKTARVY may cause serious side effects, including:

- **Worsening of hepatitis B (HBV) infection.** Your healthcare provider will test you for HBV. If you have both HIV-1 and HBV, your HBV may suddenly get worse if you stop taking BIKTARVY. Do not stop taking BIKTARVY without first talking to your healthcare provider, as they will need to check your health regularly for several months, and may give you HBV medicine.

ABOUT BIKTARVY

BIKTARVY is a complete, 1-pill, once-a-day prescription medicine used to treat HIV-1 in adults and children who weigh at least 31 pounds. It can either be used in people who have never taken HIV-1 medicines before, or people who are replacing their current HIV-1 medicines and whose healthcare provider determines they meet certain requirements.

BIKTARVY does not cure HIV-1 or AIDS. HIV-1 is the virus that causes AIDS.

Do NOT take BIKTARVY if you also take a medicine that contains:

- dofetilide
- rifampin
- any other medicines to treat HIV-1

BEFORE TAKING BIKTARVY

Tell your healthcare provider all your medical conditions, including if you:

- Have or have had any kidney or liver problems, including hepatitis infection.
- Are pregnant or plan to become pregnant.
- Are breastfeeding (nursing) or plan to breastfeed. Talk to your healthcare provider about the risks of breastfeeding during treatment with BIKTARVY.

Tell your healthcare provider about all the medicines you take:

- Keep a list that includes all prescription and over-the-counter medicines, antacids, laxatives, vitamins, and herbal supplements, and show it to your healthcare provider and pharmacist.
- Ask your healthcare provider or pharmacist about medicines that interact with BIKTARVY.

IMPORTANT FACTS

This is only a brief summary of important information about BIKTARVY® and does not replace talking to your healthcare provider about your condition and your treatment.

POSSIBLE SIDE EFFECTS OF BIKTARVY

BIKTARVY can cause serious side effects, including:

- Those in the “Most Important Information About BIKTARVY” section.
- Changes in your immune system.
- New or worse kidney problems, including kidney failure.
- Too much lactic acid in your blood (lactic acidosis), which is a serious but rare medical emergency that can lead to death. Tell your healthcare provider right away if you get these symptoms: weakness or being more tired than usual, unusual muscle pain, being short of breath or fast breathing, stomach pain with nausea and vomiting, cold or blue hands and feet, feel dizzy or lightheaded, or a fast or abnormal heartbeat.
- Severe liver problems, which in rare cases can lead to death. Tell your healthcare provider right away if you get these symptoms: skin or the white part of your eyes turns yellow, dark “tea-colored” urine, light-colored stools, loss of appetite for several days or longer, nausea, or stomach-area pain.
- **The most common side effects of BIKTARVY** in clinical studies were diarrhea (6%), nausea (6%), and headache (5%).

These are not all the possible side effects of BIKTARVY. Tell your healthcare provider right away if you have any new symptoms while taking BIKTARVY.

Your healthcare provider will need to do tests to monitor your health before and during treatment with BIKTARVY.

HOW TO TAKE BIKTARVY

Take BIKTARVY 1 time each day with or without food.

GET MORE INFORMATION

- This is only a brief summary of important information about BIKTARVY. Talk to your healthcare provider or pharmacist to learn more.
- Go to BIKTARVY.com or call 1-800-GILEAD-5.
- If you need help paying for your medicine, visit BIKTARVY.com for program information.



BIKTARVY, the BIKTARVY Logo, GILEAD, and the GILEAD Logo are trademarks of Gilead Sciences, Inc., or its related companies. Version date: August 2024
© 2025 Gilead Sciences, Inc. All rights reserved. US-BVYC-0729 02/25